Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
S.S.ORGANICS ACTAVIS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
S.S.ORGANICS Mar-23 |
ACTAVIS Dec-18 |
S.S.ORGANICS/ ACTAVIS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 41 | 16,151 | - | |
Low | Rs | 21 | 10,834 | - | |
Sales per share (Unadj.) | Rs | 21.8 | 3,961.9 | - | |
Earnings per share (Unadj.) | Rs | -8.1 | -1,276.1 | - | |
Cash flow per share (Unadj.) | Rs | -6.7 | 417.5 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | -32.5 | 16,341.1 | - | |
Shares outstanding (eoy) | m | 14.20 | 332.60 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.4 | 3.4 | 41.4% | |
Avg P/E ratio | x | -3.8 | -10.6 | 35.7% | |
P/CF ratio (eoy) | x | -4.6 | 32.3 | -14.2% | |
Price / Book Value ratio | x | -0.9 | 0.8 | -114.5% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 437 | 4,487,747 | 0.0% | |
No. of employees | `000 | NA | 16.9 | 0.0% | |
Total wages/salary | Rs m | 11 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 77,972.8 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | -25,115.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 310 | 1,317,741 | 0.0% | |
Other income | Rs m | 0 | 25,200 | 0.0% | |
Total revenues | Rs m | 310 | 1,342,940 | 0.0% | |
Gross profit | Rs m | -79 | 34,532 | -0.2% | |
Depreciation | Rs m | 21 | 563,306 | 0.0% | |
Interest | Rs m | 15 | 76,041 | 0.0% | |
Profit before tax | Rs m | -114 | -579,616 | 0.0% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 147,825 | 0.0% | |
Tax | Rs m | 2 | -7,345 | -0.0% | |
Profit after tax | Rs m | -116 | -424,445 | 0.0% | |
Gross profit margin | % | -25.3 | 2.6 | -966.9% | |
Effective tax rate | % | -1.7 | 1.3 | -137.6% | |
Net profit margin | % | -37.3 | -32.2 | 115.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 250 | 540,468 | 0.0% | |
Current liabilities | Rs m | 298 | 478,116 | 0.1% | |
Net working cap to sales | % | -15.5 | 4.7 | -328.1% | |
Current ratio | x | 0.8 | 1.1 | 74.2% | |
Inventory Days | Days | 16 | 20 | 80.9% | |
Debtors Days | Days | 119,672,906 | 66 | 180,477,652.8% | |
Net fixed assets | Rs m | 293 | 149,161 | 0.2% | |
Share capital | Rs m | 142 | 0 | - | |
Net worth | Rs m | -462 | 5,435,066 | -0.0% | |
Long term debt | Rs m | 630 | 1,913,884 | 0.0% | |
Total assets | Rs m | 543 | 8,496,244 | 0.0% | |
Interest coverage | x | -6.6 | -6.6 | 100.3% | |
Debt to equity ratio | x | -1.4 | 0.4 | -387.4% | |
Sales to assets ratio | x | 0.6 | 0.2 | 368.2% | |
Return on assets | % | -18.6 | -4.1 | 453.1% | |
Return on equity | % | 25.0 | -7.8 | -320.7% | |
Return on capital | % | -58.8 | -4.8 | 1,213.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | -16 | 470,779 | -0.0% | |
From Investments | Rs m | -96 | 258,632 | -0.0% | |
From Financial Activity | Rs m | 112 | -807,998 | -0.0% | |
Net Cashflow | Rs m | 0 | -78,195 | 0.0% |
Compare S.S.ORGANICS With: MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare S.S.ORGANICS With: SURYA PHARMA PHAARMASIA KIMIA BIOSCIENCES SYNCOM FORMULATIONS VIVIMED LABS
After opening the day marginally higher, Indian share markets reversed the trend as the session progressed and ended the day lower.